Clinical Experience Using Cell Therapy Derived from Placental Cells

Robert Hariri, M.D., Ph.D.

Chairman, Founder and CEO, Celularity, Inc.

Cells derived from the postpartum placenta have a set of unique biological properties that promise to expand the scope and utility of allogeneic cell therapies in cancer and immunological disease. Celularity’s IMPACT platform uniquely accelerates the clinical development of allogeneic cell therapies, the scalability and affordability of which is a function of a near-limitless supply of eligible donor placentas. In immuno-oncology, placental-drived NK cells (PNK) demonstrate intrinsic cytotoxic activity in tumor cells without alloimmune (GvHD) or autoimmune toxicities. Celularity’s PNK-007 product has demonstrated therapeutic promise and promising safety signals in AML and multiple myeloma.